The IFT88 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of A2780 cells with targeted disruption of the IFT88 gene, providing a loss-of-function model to study intraflagellar transport and primary cilium signaling. This heterogeneous knockout pool avoids clonal artifacts and is suitable for population-based functional genomics approaches.
The A2780 cell line is an epithelial human ovarian carcinoma model widely used for investigating tumor biology and drug responses, including platinum-based chemotherapy sensitivity. This background enables exploration of ciliary functions in a clinically relevant ovarian cancer context.
IFT88 is a crucial component of the IFT-B complex, mediating anterograde and retrograde trafficking essential for ciliogenesis. Its expression is regulated by RFX transcription factors and RAB8A, and it interacts with IFT52, IFT57, kinesin-2, and dynein-2. IFT88 loss abolishes primary cilium formation, disrupting Hedgehog signaling through SMO, PTCH1, and GLI transcription factors, while also altering Wnt pathway dynamics via ??-catenin. Thus, IFT88 acts as a central node coordinating ciliary signal transduction that influences proliferation and differentiation.
In the A2780 ovarian carcinoma setting, IFT88 knockout allows dissection of primary cilia contributions to cancer cell phenotypes such as migration, cell cycle progression, and drug sensitivity. The interplay between ciliary Hedgehog/Wnt signaling and ovarian cancer pathology can be systematically examined, potentially uncovering therapeutic vulnerabilities linked to ciliary dysfunction.
Applications include ciliopathy research, Hedgehog/Wnt crosstalk studies, and drug sensitivity profiling. Key assays involve immunofluorescence for ciliary markers, western blotting for IFT88/GLI, RT-qPCR, migration assays, and flow cytometry for cell cycle analysis. The polyclonal design supports robust population-level gene function studies. For further inquiries, contact Ascent Research.
